

RESEARCH

Open Access



SIRT1 prevents cigarette smoking-induced lung fibroblasts activation by regulating mitochondrial oxidative stress and lipid metabolism

Yue Zhang^{1†}, Ting Li^{1†}, Miaoxia Pan^{1†}, Wei Wang¹, Wenhui Huang¹, Yafei Yuan¹, Zhanzhan Xie¹, Yixin Chen¹, Jun Peng¹, Xu Li^{2,3*} and Ying Meng^{1*}

Abstract

Background: Cigarette smoking (CS) is a strong risk factor for idiopathic pulmonary fibrosis (IPF). It can activate lung fibroblasts (LF) by inducing redox imbalance. We previously showed that clearing mitochondrial reactive oxygen species (mtROS) protects against CS-induced pulmonary fibrosis. However, the precise mechanisms of mtROS in LF need further investigation. Here we focused on mtROS to elucidate how it was regulated by CS in LF and how it contributed to LF activation.

Methods: We treated cells with 1% cigarette smoking extract (CSE) and examined mtROS level by MitoSOX™ indicator. And the effect of CSE on expression of SIRT1, SOD2, mitochondrial NOX4 (mtNOX4), fatty acid oxidation (FAO)-related protein PPARα and CPT1a and LF activation marker Collagen I and α-SMA were detected. Nile Red staining was performed to show cellular lipid content. Then, lipid droplets, autophagosome and lysosome were marked by Bodipy 493/503, LC3 and LAMP1, respectively. And lipophagy was evaluated by the colocalization of lipid droplets with LC3 and LAMP1. The role of autophagy on lipid metabolism and LF activation were explored. Additionally, the effect of mitochondria-targeted ROS scavenger mitoquinone and SIRT1 activator SRT1720 on mitochondrial oxidative stress, autophagy flux, lipid metabolism and LF activation were investigated in vitro and in vivo.

Results: We found that CS promoted mtROS production by increasing mtNOX4 and decreasing SOD2. Next, we proved mtROS inhibited the expression of PPARα and CPT1a. It also reduced lipophagy and upregulated cellular lipid content, suggesting lipid metabolism was disturbed by CS. In addition, we showed both insufficient FAO and lipophagy resulted from blocked autophagy flux caused by mtROS. Moreover, we uncovered decreased SIRT1 was responsible for mitochondrial redox imbalance. Furthermore, we proved that both SRT1720 and mitoquinone counteracted the effect of CS on NOX4, SOD2, PPARα and CPT1a in vivo.

[†]Yue Zhang, Ting Li and Miaoxia Pan contributed equally to this work.

*Correspondence: mylx99@smu.edu.cn; nfyymengy@163.com

¹ Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

² Department of Emergency Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Full list of author information is available at the end of the article



Conclusions: We demonstrated that CS decreased SIRT1 to activate LF through dysregulating lipid metabolism, which was due to increased mtROS and impaired autophagy flux. These events may serve as therapeutic targets for IPF patients.

Keywords: Cigarette smoking, SIRT1, Mitochondrial oxidative stress, Autophagy, Lipid metabolism

Introduction

Mitochondrial oxidative stress is a critical player in idiopathic pulmonary fibrosis (IPF) [1] and TGF- β -induced lung fibroblast (LF) activation [2]. Targeting mitochondrial reactive oxygen species (mtROS) can alleviate CS-related lung fibrosis in vivo [3]. Lung fibroblasts (LF) are effector cells in the pathogenesis of IPF. It can be activated by CS [4]. However, whether mtROS of LF was induced by CS and how mtROS activated LF is uncertain. NADPH oxidases (NOXs) is one of the main sources of ROS. In LF isolated from IPF patients, NOX4 is elevated while NOX1, 2 and 5 have no significant change [5]. In addition, NOX4 can be upregulated by CS [4]. Several lines of evidences manifested that NOX4 can be located in mitochondria since it contains a mitochondrial targeting signal [1]. Thus, we aim to investigate whether and how CS increased mitochondrial NOX4 (mtNOX4) and thereby produced more mtROS.

Mitochondria is the powerhouse and center of metabolism in eukaryotic cells. Evidences indicated that mitochondrial oxidative stress is closely associated with metabolic disorders [6]. In fibrotic lungs, fatty acid (FA) and total lipid content [7] are increased. And high fat diet can aggravate experimental pulmonary fibrosis [8], implying lipid metabolism participates in lung fibrosis. In addition, lipid metabolism can be affected by CS [9]. However, whether CS-induced mitochondrial oxidative stress dysregulated lipid metabolism and subsequently activated LF and its underlying mechanisms are unclear. Fatty acid oxidation (FAO), for which mitochondria is an important place, is a process closely associated with lipid homeostasis. CPT1a is a key rate-limiting enzyme of mitochondrial FAO and is reported to be involved in fibrotic diseases, such as kidney [10] and liver fibrosis [11]. Moreover, its upstream regulator, PPAR α , also exhibits anti-fibrotic effect in liver [12], kidney [13], heart [14] and lung [15]. Therefore, its noteworthy to find out whether CS-induced mtROS activated LF through dysregulating PPAR α /CPT1a-mediated FAO and lipid metabolism, which may be targets for lung fibrosis therapy.

SIRT1, a lysine deacetylase, is a modulator of mitochondrial oxidative stress [3] and NOX4 expression [16]. It has been reported that its anti-fibrotic effect is associated with decreased mtROS [3, 17]. It can also inhibit fibroblasts activation [3, 17] and modulate lipid

metabolism [19]. However, whether SIRT1 protect against LF activation by regulating mtNOX4-related mtROS and lipid metabolism and its mechanisms need to be further investigated.

In the present study, we explored how mitochondrial redox balance was disrupted by CS and how mtROS activated LF. We found imbalance of mtNOX4 and SOD2 resulting from decreased SIRT1 was responsible for CS-induced mtROS. mtROS impaired autophagy flux to activate LF by inhibiting PPAR α /CPT1-related FAO and lipophagy.

Materials and methods

Animals

Six-week-old male C57 mice were randomly divided into four groups: Control, CS, CS + MitoQ (1.5 mg/kg, HY-100116, MCE), CS + SRT1720 (20 mg/kg, S1129, Selleck). 10 mice in each group. In the three CS groups, mice were placed in an 80 × 35 × 33 cm chamber and exposed to 5 commercial cigarettes for 30 min each time, and two times a day. For MitoQ and SRT1720 group, MitoQ and SRT1720 were injected intraperitoneally into mice every two days or each day, respectively. 4 weeks later, lungs were harvested. All mice were obtained from Southern Medical University Animal Center (Guangzhou, China) and housed in standard environment. All experimental procedures on mice were approved by Committee on the Ethics of Animal Experiments of Southern Medical University (Permit No. SYXK 2015-0056).

Cell culture and treatment

Primary LF were isolated from 6-week-old mice as previously described [20] and cultured with DMEM containing 15% FBS at 37 °C. Passage 2 cells were treated with MitoQ (50 nM, HY-100116, MCE), fenofibrate (10 μ M, T1149, Topscience), oleic acid (10 μ M, S4707, Selleck), etomoxir (50 μ M, S8244, Selleck), bafilomycin (5 nM, S1413, Selleck) and SRT1720 (4 μ M, S1129, Selleck) (Additional file 1). The dosages of these compounds were based on published papers. And MTT test for them was performed (Additional file 2).

Preparation of cigarette smoke extract (CSE)

Firstly, smoke of 1 cigarette was collected by a 20 ml syringe which contained 2 ml PBS. Then, the absorbance of the solution was detected at the wavelength of 490 nm.

The concentration was considered as 100% when the absorbance was 0.1. Next, adjusted its pH to 7.4 and filtered it with 0.2 μm membrane. The obtained CSE was kept in 4 °C and applied within 20 min.

MitoSOX red, lysotracker red, Nile red and BODIPY 493/503 staining

Living cells were incubated with MitoSOX™ Red (2.5 μM , M36008, Invitrogen), LysoTracker Red DND-99 (50 nM, L7528, Invitrogen), Nile Red (1 μM , HY-D0718, MCE) or BODIPY staining solution (2 μM , GC42959, GLPBIO) for 15 min at 37 °C in dark. Then, cells were washed with HBSS/Ca/Mg and analyzed by fluorescence microscopy (IX73, Olympus or Imager D2, Carl Zeiss).

Immunofluorescence staining

Lung sections or cells treated with 4% paraformaldehyde for 15 min and 0.2% Triton for 10 min were blocked with 5% goat serum for 60 min at room temperature. Then, they were incubated with primary antibodies at 4 °C for overnight and stained with FITC- (A0562, Beyotime) and Coralite594-conjugated secondary antibody (SA00013-4, Proteintech) at room temperature for 1 h, after which nuclear were stained with DAPI (F6057, Sigma). Pictures were captured with confocal microscopy (LSM880, Carl Zeiss) or fluorescence microscopy (Imager D2, Carl Zeiss). Primary antibodies used here were as follows: anti-NOX4 (ab154244, Abcam), anti-COX IV (200147, ZENBIO), anti-LC3 II/I (A5179, Bimake), anti-SOD2 (A5377, Bimake), anti-collagen I (ABM40379, Abbkine), anti-CPT1a (15184-1-AP, Proteintech) and anti-PPAR α (Abp55667, Abbkine).

Western blot analysis

The relative expression of total protein or mitochondrial protein were detected by western blot. Antibodies used here were as follows: Collagen I (ab260043, Abcam), α -SMA (ab7817, Abcam), VDAC1 (A5224, Bimake), p62 (18420-1-AP, Proteintech), LC3 II/I (A5179, Bimake), SIRT1 (13161-1-AP, Proteintech), GAPDH (RM2001; Ray Antibody Biotech), and secondary antibodies (92632210, 92632211, Licor). The bands were visualized by Odyssey System (LI-COR).

Statistical analysis

Results were shown as mean \pm SD. Data analysis were performed by SPSS 22.0 (SPSS Inc., Chicago, IL, USA). Intergroup comparison of the mean values was analyzed by one-way analysis of variance (ANOVA). Statistical significance was defined as $p < 0.05$.

Results


Cigarette smoke extract (CSE) increased mtNOX4/SOD2-mediated mtROS to activate primary LF

To make clear the effect of CSE on mtROS, we incubated LF with MitoSOX Red, a mitochondria specific superoxide indicator. Results showed that mtROS was promoted by CSE (Fig. 1A). The colocalization of NOX4 with COX IV, a mitochondrial marker, was upregulated (Fig. 1B). The protein level of NOX4 in mitochondrial lysate was also elevated, indicating CSE increased mtNOX4 (Fig. 1C). Since oxidative stress is a result of the imbalance of ROS production and cellular antioxidant defense, we detected the expression of SOD2, the main antioxidant in mitochondria. And we found SOD2 was decreased (Fig. 1C), suggesting mitochondrial redox balance was disturbed. Furthermore, results showed mitochondria-targeted antioxidant mitoquinone (MitoQ) inhibited the expression of collagen I and α -SMA (Fig. 1D), two markers of LF activation, coupled with decreased mtROS and mtNOX4 level and increased SOD2 expression (Fig. 1A, C). Therefore, CSE activated LF by increasing mtROS which may be due to the imbalance of mtNOX4 and SOD2.

mtROS activated LF by decreasing PPAR α /CPT1a-mediated fatty acid oxidation (FAO)

Next, we found lipid deposition was increased as indicated by Nile Red staining (Fig. 2A), while CPT1a and PPAR α expression was downregulated (Fig. 2B), indicating lipid metabolism was altered by CSE. Then, results showed PPAR α activator fenofibrate (Feno) elevated CPT1a level (Fig. 2C) and decreased lipid deposition (Fig. 2A). Furthermore, we found it downregulated the expression of CSE-induced collagen I and α -SMA (Fig. 2D). And both the etomoxir (ETO), a selective inhibitor of CPT1a, and extracellular oleic acid (OA), a fatty acid that was upregulated in fibrotic lungs [21], erased the effect of Feno on collagen I and α -SMA (Fig. 2D). Therefore, CSE decreased PPAR α /CPT1a-mediated FAO, which resulted in increased lipid deposition to activate LF.

Then, we examined the effect of mtROS on PPAR α /CPT1a-mediated lipid metabolism. Results showed MitoQ increased the level of PPAR α and CPT1a and declined lipid deposition (Fig. 2E, F). Moreover, both ETO and OA eliminated the inhibitory effect of MitoQ on collagen I and α -SMA (Fig. 2G), suggesting CSE-induced mtROS impaired PPAR α /CPT1a-mediated lipid metabolism to activate LF.



mtROS dysregulated lipid metabolism by impairing autophagy flux

Lipophagy refers to a process in which the lipid droplets (LDs) are engulfed by autophagosomes and subsequently degraded by lysosomes [22]. It is crucial for lipid homeostasis. We previously revealed that CSE blocked autophagy flux by impairing lysosomes [4]. To find out whether lipophagy was also impaired, LDs were marked by BODIPY 493/503. Results showed that CSE had no effect on the co-localization of LDs with LC3 (Fig. 3A), but decreased the co-localization of LDs with lysosomes, which was stained by LysoTracker Red, an indicator of lysosomes (Fig. 3B), suggesting lipophagy was inhibited by CSE. Next, we explored the regulatory effect of mtROS on lipophagy. We found that MitoQ restored lipophagy (Fig. 3A, B), coupled with improved autophagy flux as indicated by decreased level of LC3 II and p62 and number of autophagosomes and increased number of autolysosomes (Fig. 3C, D). However, in the presence of bafilomycin (BA), a blocker of autophagy flux, lipophagy cannot be induced by MitoQ (Fig. 3A, B), indicating CSE-induced mtROS inhibited lipophagy by disrupting autophagy flux. Not only lipophagy, the effect of MitoQ on PPAR α , CPT1a, lipid content, collagen I and α -SMA was also inhibited by BA (Fig. 3E,

F), demonstrating CSE-induced mtROS activated LF by impairing autophagy flux which inhibited lipophagy as well as PPAR α /CPT1a-mediated FAO.

Interestingly, in the absence of CSE, ETO or OA treatment for 24 h failed to induce LF activation (Fig. 3G). Moreover, lipid content was increased at 3 h while back to baseline level at 24 h (Fig. 3H, I), suggesting LF may have compensatory capacity for lipid metabolism. Then, we explored whether the capacity was associated with autophagy. And we found that after blocking autophagy flux for 24 h by BA, lipid deposition was increased by ETO or OA alone (Fig. 3I). Furthermore, we found the number of autolysosomes were increased at the early time of ETO or OA treatment (Fig. 3J). Consistently, LC3II was upregulated (Fig. 3K). It can be further elevated by BA, which suggested autophagy was activated by ETO or OA in the absence of CSE. Taken together, LF had compensatory capacity for lipid metabolism, which may be modulated by autophagy. These results further confirmed the essential role of autophagy in lipid homeostasis of LF.

SIRT1 prevented CSE-induced LF activation by regulating lipid metabolism in an autophagy-dependent pathway

Then, we found SIRT1 expression in LF was decreased by CSE (Fig. 4A). Activating SIRT1 by its activator SRT1720 downregulated the level of collagen I and




Fig. 2 CSE-induced mitochondrial oxidative stress dysregulated lipid metabolism to activate LF. **A** Nile Red staining was performed to show lipid content in cells treated as indicated. **B** The effect of CSE on protein level of CPT1a and PPARα which were related with FAO. **C** The effect of PPARα activator Feno on CPT1a level. **D** Western blot to determine the level of Collagen I and α-SMA. **E** The role of MitoQ in CPT1a and PPARα expression. **F** Nile Red staining. **G** Western blot analysis for Collagen I and α-SMA expression. * $p < 0.05$ versus control, # $p < 0.05$ versus CSE, & $p < 0.05$ versus CSE + Feno or CSE + MitoQ. Feno fenofibrate, ETO etomoxir, OA oleic acid

(See figure on next page.)

Fig. 3 mtROS disturbed lipid metabolism by impaired autophagy flux, which decreased PPARα/CPT1a and lipophagy. **A, B** Lipophagy was shown as the co-localization of LC3 (red) (A) or LTR (red) (B) with LDs indicated by Bodipy 493/503 (green). **C** Protein level of p62, LC3 I and LC3 II. **D** Cells transfected with mRFP-GFP-LC3 adenovirus were treated with CES and MitoQ for 24 h. Then, pictures were captured. Yellow dots were autophagosomes and red were autolysosomes. **E** Protein level of collagen I, α-SMA, PPARα and CPT1a in each group. **F** Lipid content was assessed by Nile Red staining. * $p < 0.05$ versus control, # $p < 0.05$ versus CSE, & $p < 0.05$ versus CSE + MitoQ (n = 3). **G** Protein level of collagen I and α-SMA of cells treated with ETO or OA alone for 24 h. **H** Nile Red staining was performed to examine lipid content of cells stimulated with ETO or OA for 3 h. **I** Cells pretreated with or without BA for 1 h were treated with ETO or OA for 24 h. Then lipid content was evaluated by Nile Red staining. **J** Autophagosomes (yellow) and autolysosomes (red) were observed. **K** Cells pretreated with or without BA for 1 h were stimulated with ETO or OA for 3 h. Then protein level of LC3 I and LC3 II were detected. * $p < 0.05$ versus control, # $p < 0.05$ versus ETO, & $p < 0.05$ versus OA (n = 3). BA bafilomycin, LTR lysotracker red




Fig. 3 (See legend on previous page.)




Fig. 4 SIRT1 prevented CSE-induced LF activation by regulating lipid metabolism in an autophagy-dependent pathway. **A** Level of SIRT1 was detected. **B** Effect of SIRT1 activator SRT1720 on the expression of Collagen I, α -SMA, CPT1a and PPAR α . **C** Nile Red Staining. **D, E** Representative pictures of lipophagy as indicated by the co-localization of LC3 (**D**) or LTR (**E**) with Bodipy 493/503. **F, G** Western blot analysis for Collagen I, α -SMA, p62, LC3 I and LC3 II. **H** Representative pictures and numbers of autophagosomes (yellow) and autolysosomes (red). **I** Level of collagen I, α -SMA, CPT1a and PPAR α were examined. * $p < 0.05$ versus control, # $p < 0.05$ versus CSE, & $p < 0.05$ versus CSE + SRT1720 (n = 3)

α -SMA (Fig. 4B), indicating CSE activated LF by inhibiting SIRT1 expression. Next, we explored whether the effect of SIRT1 on LF activation was mediated by lipid metabolism. Results showed SRT1720 increased PPAR α and CPT1a level (Fig. 4B) and decreased lipid deposition (Fig. 4C). Although it did not change the colocalization of LDs with LC3 (Fig. 4D), the colocalization of LDs with lysosomes was increased (Fig. 4E). Furthermore, the inhibitory effect of SRT1720 on LF activation was reversed by ETO and OA (Fig. 4F). Thus, CSE dysregulated PPAR α /CPT1a and lipophagy by suppressing SIRT1.

Moreover, we found LC3 II and p62 expression (Fig. 4G) and number of autophagosomes were decreased and autolysosomes was increased by SRT1720 (Fig. 4H), which suggested CSE impaired autophagy flux through reducing SIRT1. To make clear whether SIRT1 modulated lipid metabolism and LF activation in an autophagy-dependent pathway, BA were used to pre-treat cells. And results showed SRT1720 failed to regulate the expression of collagen I, α -SMA, PPAR α and CPT1a (Fig. 4I), lipophagy (Fig. 4D, E) and lipid deposition (Fig. 4C) in BA-pretreated cells. Consequently, these results demonstrated that SIRT1 inhibited CSE-induced LF activation by modulating lipid metabolism in an autophagy-dependent pathway.

The protective effect of SIRT1 was associated with mitochondrial redox balance

Results showed in CSE-treated cells, SRT1720 decreased mtNOX4 and elevated SOD2 (Fig. 5A), couple with declined mtROS (Fig. 5B). Furthermore, we knocked down SOD2 and found that SOD2 siRNA blocked the effect of SRT1720 on autophagy flux (Fig. 5C, D), lipophagy (Fig. 5E, F), lipid accumulation (Fig. 5G) and the expression of PPAR α , CPT1a, collagen I and α -SMA (Fig. 5H). These results demonstrated that the effect of SIRT1 on lipid metabolism and LF activation was mediated by mitochondrial oxidative stress.

Clearing mtROS or activating SIRT1 can prevent LF activation, increase PPAR α and CPT1a expression of LF in vivo

We previously revealed that MitoQ and SRT1720 can mitigate CS-induced pulmonary fibrosis [3]. Here we chose collagen I as the marker of LF based on two single-cell sequencing studies [23, 24] to further confirm the role of MitoQ and SRT1720 in mitochondrial oxidative stress and lipid metabolism of LF in smoking mice. And we found MitoQ decreased the level of collagen I (Fig. 6A) and increased the level of PPAR α and CPT1a of LF (Fig. 6A).

Furthermore, we showed SIRT1 in LF of mice exposed to smoke was reduced (Fig. 6B). SRT1720 declined the level of collagen I in lungs (Fig. 6A). Moreover, in LF, NOX4 was downregulated by SRT1720 and SOD2, PPAR α and CPT1a was increased (Fig. 6A, C). Therefore, clearing mtROS or targeting SIRT1 can regulate mitochondrial oxidative stress, FAO and protect against activation of LF in smoking mice.

Discussion

In the present study, we centered on mtROS to explore how it was regulated by CS and how it contributed to LF activation. Our results showed that CS-induced mtROS was due to the imbalance of mtNOX4 and SOD2 caused by decreased SIRT1. And it activated LF by dysregulating PPAR α /CPT1a-mediated FAO and lipophagy, both of which resulted from blocked autophagy flux (Fig. 6D).

mtROS, a critical player in IPF development and LF activation [25], can be induced by CS in a variety of cells [3, 26–28]. Our previous study has suggested mtROS may be a therapeutic target for CS-related pulmonary fibrosis [3]. However, how it worked in LF is incompletely known. In the present study, we explored how CS regulated mtROS and how mtROS participated in CS-induced LF activation. We previously proved increased NOX4 was a contributor of LF activation [4]. Studies reported that NOX4 can be localized in mitochondria and the elevation of mtNOX4 was related with LF activation [4]. Here we demonstrated CSE increased mtNOX4. And consistent with previous researches [27], we also evidenced the expression of SOD2, the main antioxidant enzyme of mitochondria, was reduced. Therefore, CSE disrupted mitochondrial redox balance. Furthermore, we first unveiled the inhibitory effect of MitoQ on LF activation. Similarly, studies also demonstrated MitoQ can prevent the activation of cardiac and nasal fibroblast [29, 30]. In addition, the antifibrotic effect of MitoQ has been evidenced in lung [3], liver [31] and kidney [32]. Moreover, the safety of MitoQ has been confirmed by Phase II clinical trials [33]. Altogether, MitoQ may be an effective and safety treatment for IPF or other smoking-related disease.

Lipid metabolism has been reported to be disrupted in fibrotic lungs [7, 34] and participate in fibroblast activation [35]. It can also be dysregulated by CS [9]. As lipid metabolism is closely modulated by mitochondria, we explored whether CS-induced mtROS activated LF by dysregulating lipid metabolism. Firstly, we examined the expression of CPT1a, since it is a key rate-limiting enzyme of mitochondrial FAO and is involved in kidney [10] and liver fibrosis [11]. And we found CSE downregulated CPT1a of LF. In addition, we proved that PPAR α , the upstream regulator of CPT1a, was also inhibited.





Fig. 5 The protective effect of SIRT1 was mediated by mitochondrial redox balance. **A** Level of SOD2 and mtNOX4. **B** mtROS level were examined by mitoSOX indicator. **C** Autophagosomes (yellow) and autolysosomes (red) were evaluated. **D** SOD2 were knocked down by siRNA, followed by CSE and SRT1720 treatment. Then, p62, LC3 I and LC3 II expression was determined. **E-F** LC3 (**E**) and lysosome (**F**) and LDs were stained to show lipophagy. **G** Cellular lipid content was evaluated by Nile Red staining. **H** Expression of collagen I, α -SMA, CPT1a and PPAR α . * $p < 0.05$ versus control, # $p < 0.05$ versus CSE, & $p < 0.05$ versus CSE + SRT1720 (n = 3)



Consistent with previous study that PPARα activators exert anti-fibrotic effects in liver [12], kidney [13], heart [14] and lung [15], we revealed that PPARα activator prevented CSE-induced LF activation by elevating CPT1a. Furthermore, we proved that decreased FAO was due to mtROS. CPT1a inhibitor ETO as well as oleic acid, a fatty acid that is upregulated in the plasm of IPF patients [36] and has pro-fibrotic effect [37], can inhibit the anti-fibrotic effect of mitoQ, demonstrating that mtROS activated LF by dysregulating PPARα/CPT1a-related FAO. These results implying that pulmonary lipid metabolic state may have diagnosis potential for IPF. And interfering it may be effective for IPF.

To make clear how mtROS dysregulated lipid metabolism, we paid our attention to autophagy due to following

reasons. Firstly, autophagy can prevent LF activation and fibrosis through multiple pathways [38, 39], but how it worked on lipid metabolism in CSE-treated LF is rarely explored. Secondly, autophagy is critical for mitochondrial homeostasis [40] which plays an important role in lipid metabolism. And our previous studies showed autophagy flux was impaired by CSE in an oxidative stress-related pathway [4]. Thirdly, compelling evidences indicated lipophagy, a process of autophagy-mediated LDs degradation, is necessary for lipid homeostasis [22]. Abnormal lipophagy has also been reported to be involved in fibrotic diseases [41]. Therefore, it is reasonable to postulate that CSE-induced mtROS disrupt lipid metabolism in an autophagy dependent pathway. As we expected, we found autophagy flux can be blocked by

mtROS. And it played an essential role in lipid metabolism not only by regulating PPAR α and CPT1a but also inhibiting lipophagy. In addition, our results indicated that mtROS did not influence the transfer of LDs to autophagosomes, but inhibited the transfer of LDs to lysosomes. This result was consistent with our previous finding that CS-induced dysfunction of lysosome contributed to impaired autophagy flux [4]. We supposed the effect of autophagy on PPAR α /CPT1a-mediated FAO was associated with mitophagy, a process essential for mitochondrial homeostasis. However, the regulatory effect of lipophagy on FAO has also been reported [22]. Therefore, it still needs to be explored whether autophagy regulated FAO by mitophagy or lipophagy. The importance of autophagy in lipid metabolism was further confirmed by results that CSE-untreated LF has compensatory capacity for lipid homeostasis maintenance in the presence of ETO or OA. However, in BA-treated LF, the capacity was lost even in the absence of CSE. Thus, CSE-induced mtROS blocked autophagy flux to dysregulated lipid metabolism by inhibiting PPAR α /CPT1a and lipophagy. The study further revealed the mechanism of autophagy in pulmonary fibrosis.

As we mentioned above, mtNOX4/SOD2-mediated mtROS played a critical role in CSE-induced LF activation. Hence, it is noteworthy to find the mechanism by which CSE disrupt the balance of mtNOX4 and SOD2. In the present study, we focused on SIRT1. For one thing, the negative effect of SIRT1 on mitochondrial oxidative stress has been confirmed in multiple organs, such as kidney [42], liver [43] and lung [3]. Moreover, it has been reported that NOX4 and SOD2 can be modulated by SIRT1 [16, 44]. For another, its anti-fibrotic effect has been confirmed in pulmonary fibrosis [18, 45]. And studies showed SIRT1 can protect against TGF- β -induced LF activation [18]. It also modulates lipid metabolism [19] and autophagy [3]. However, whether it can rebalance mtNOX4 and SOD2 and thereby regulate autophagy and lipid metabolism to protect against CSE-induced LF activation is uncertain. Here, we uncovered that SIRT1 rescued autophagy flux by rebalancing mtNOX4 and SOD2. And it promoted lipophagy and PPAR α /CPT1a expression in an autophagy-dependent pathway. Therefore, activating SIRT1 may be a valuable treatment against pulmonary fibrosis or CS-related disorders. However, there are still some challenges, since changes of SIRT1 is complex. For example, CSE inhibited SIRT1 activity in alveolar epithelial type II cells [3] but decreased SIRT1 expression in LF. This reminded us that it would be more rational to perform different interventions in different cell types because of the complexity of the human body,

although the anti-fibrotic effect of whole body SRT1720 stimulation has been confirmed in mice.

The utility of α -SMA as the marker of activated LF was challenged recent years as it was only upregulated in a subset of these cells [23]. Moreover, in lungs of control mice, α -SMA-positive LF is rarely detected, which make it difficult to compare the difference of indicators between control and pro-fibrotic LF in vivo. A present unbiased single-cell RNA sequencing study revealed that *coll1a1* is expressed in 99.8% activated LF, 80.4% non-activated LF and 4.7% non-LF. Although not a perfect marker, it is better than others such as α -SMA, which is expressed in 63.6% activated LF, 11% nonactivated LF and 4.1% non-LF [23]. The superiority and rationality of *coll1a1* as the marker of LF was further confirmed by another single-cell RNA sequencing study [24]. So, we chose *coll1a1* as the marker of LF to detect the different expression of above indicator in LF in vivo.

Conclusion

Taken together, we demonstrated CS-induced mtNOX4/SOD2 mediated mtROS contributed to LF activation by decreasing PPAR α /CPT1a-mediated FAO and lipophagy, which resulted from blocked autophagy flux. The reduction of SIRT1 expression was responsible for CS-induced mitochondrial oxidative stress. Consequently, CS decreased SIRT1 to activate LF by promoting mitochondrial oxidative stress, which dysregulated lipid metabolism through impairing autophagy flux. Targeting these events may have therapeutic effect for pulmonary fibrosis.

Abbreviations

BA: Bafilomycin; CS: Cigarette smoking; CSE: Cigarette smoke extract; ETO: Etomoxir; FA: Fatty acid; FAO: Fatty acid oxidation; Feno: Fenofibrate; IPF: Idiopathic pulmonary fibrosis; LDs: Lipid droplets; LF: Lung fibroblast; mtNOX4: Mitochondrial NADPH oxidase 4; mtROS: Mitochondrial reactive oxygen species; MitoQ: Mitoquinone; OA: Oleic acid.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12967-022-03408-5>.

Additional file 1 Original blots of Western Blot analysis. The figure legend of this file is the same as the legend of the corresponding figure in the main text.

Additional file 2 MTT test for compounds used to treat cells. Cells were treated as indicated and their concentrations were showed in Materials and Methods section. Then, MTT tests were performed following manufacture's instruction (Beyond, Shanghai, China). CSE cigarette smoke extract, MitoQ mitoquinone, Feno fenofibrate, OA oleic acid, ETO etomoxir, BA bafilomycin.

Acknowledgements

Not applicable.

Author contributions

YM: conceptualization, validation, resources, data curation, writing—review and editing, supervision, project administration, funding acquisition; XL: conceptualization, validation, resources, data curation, writing—review and editing, supervision, project administration, funding acquisition; YZ: methodology, validation, formal analysis, investigation, writing—original draft preparation; TL: methodology, formal analysis, investigation, funding acquisition; MXP: methodology, software, formal analysis, investigation, funding acquisition; WW: methodology, software, formal analysis, investigation; WHH: software, formal analysis, investigation; YFY: formal analysis; ZZK: investigation; YXC: investigation; JP: formal analysis. All authors read and approved the final manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (Grant Numbers 81870068, 81900066, 82070063), Natural Science Foundation of Guangdong province (Grant Number 2019A1515012110, 2021A1515012595), Key Laboratory of Emergency and Trauma (Hainan Medical University), Ministry of Education (Grant Number KLET-202102) and Youth Project of Dean's Fund of Nanfang Hospital, Southern Medical University (Grant Number 2019C006).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Declarations**Ethics approval and consent to participate**

All experimental procedures on mice were approved by Committee on the Ethics of Animal Experiments of Southern Medical University (Permit No. SYXK 2015-0056).

Consent for publication

Yes.

Competing Interests

The authors declare that they have no competing interests.

Author details

¹Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. ²Department of Emergency Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. ³Ministry of Education, Key Laboratory of Hainan Trauma and Disaster Rescue, College of Emergency and Trauma, Hainan Medical University, Haikou, China.

Received: 11 February 2022 Accepted: 24 April 2022

Published online: 14 May 2022

References

1. Veith C, Boots AW, Idris M, van Schooten FJ, van der Vliet A. Redox imbalance in idiopathic pulmonary fibrosis: a role for oxidant cross-talk between NADPH oxidase enzymes and mitochondria. *Antioxid Redox Signal*. 2019;31(14):1092–115.
2. Huang LS, Jiang P, Feghali-Bostwick C, Reddy SP, Garcia J, Natarajan V. Lysocardiolipin acyltransferase regulates TGF- β mediated lung fibroblast differentiation. *Free Radic Biol Med*. 2017;112:162–73.
3. Zhang Y, Huang W, Zheng Z, Wang W, Yuan Y, Hong Q, et al. Cigarette smoke-inactivated SIRT1 promotes autophagy-dependent senescence of alveolar epithelial type 2 cells to induce pulmonary fibrosis. *Free Radic Biol Med*. 2021;166:116–27.
4. Pan M, Zheng Z, Chen Y, Sun N, Zheng B, Yang Q, et al. Angiotensin-(1–7) attenuated cigarette smoking-related pulmonary fibrosis via improving the impaired autophagy caused by nicotinamide adenine dinucleotide phosphate reduced oxidase 4-dependent reactive oxygen species. *Am J Respir Cell Mol Biol*. 2018;59(3):306–19.
5. Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGF β 1-induced fibroblast differentiation into myofibroblasts. *Thorax*. 2010;65(8):733–8.
6. Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders—a step towards mitochondria based therapeutic strategies. *Biochim Biophys Acta Mol Basis Dis*. 2017;1863(5):1066–77.
7. Kulkarni YM, Dutta S, Iyer A, Wright CA, Ramesh V, Kaushik V, et al. A lipidomics approach to identifying key lipid species Involved in VEGF-inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis. *Proteomics Clin Appl*. 2018;12(3): e1700086.
8. Chu SG, Villalba JA, Liang X, Xiong K, Tsoyi K, Ith B, et al. Palmitic acid-rich high-fat diet exacerbates experimental pulmonary fibrosis by modulating endoplasmic reticulum stress. *Am J Respir Cell Mol Biol*. 2019;61(6):737–46.
9. Gong J, Zhao H, Liu T, Li L, Cheng E, Zhi S, et al. Cigarette smoke reduces fatty acid catabolism, leading to apoptosis in lung endothelial cells: implication for pathogenesis of COPD. *Front Pharmacol*. 2019;10:941.
10. Miguel V, Tituana J, Herrero JI, Herrero L, Serra D, Cuevas P, et al. Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis. *J Clin Invest*. 2021;131(5):e140695.
11. Zhao Q, Wei M, Zhang S, Huang Z, Lu B, Ji L. The water extract of *Sophorae tonkinensis* Radix et rhizoma alleviates non-alcoholic fatty liver disease and its mechanism. *Phytomedicine*. 2020;77: 153270.
12. Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPAR α action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. *J Hepatol*. 2015;62(3):720–33.
13. Chung KW, Lee EK, Lee MK, Oh GT, Yu BP, Chung HY. Impairment of PPAR α and the fatty acid oxidation pathway aggravates renal fibrosis during aging. *J Am Soc Nephrol*. 2018;29(4):1223–37.
14. Sarma S, Ardehali H, Gheorghide M. Enhancing the metabolic substrate: PPAR- α agonists in heart failure. *Heart Fail Rev*. 2012;17(1):35–43.
15. Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, Sime PJ. The role of PPARs in lung fibrosis. *PPAR Res*. 2007;2007:71323.
16. Dasgupta A, Shukla SK, Vernucci E, King RJ, Abrego J, Mulder SE, et al. SIRT1-NOX4 signaling axis regulates cancer cachexia. *J Exp Med*. 2020;217(7):e20190745.
17. Wu K, Li B, Lin Q, Xu W, Zuo W, Li J, et al. Nicotinamide mononucleotide attenuates isoproterenol-induced cardiac fibrosis by regulating oxidative stress and Smad3 acetylation. *Life Sci*. 2021;274:119299.
18. Chu H, Jiang S, Liu Q, Ma Y, Zhu X, Liang M, et al. Sirtuin1 protects against systemic sclerosis-related pulmonary fibrosis by decreasing proinflammatory and profibrotic processes. *Am J Respir Cell Mol Biol*. 2018;58(1):28–39.
19. Deleye Y, Cotte AK, Hannou SA, Hennuyer N, Bernard L, Derudas B, et al. CDKN2A/p16INK4a suppresses hepatic fatty acid oxidation through the AMPK α 2-SIRT1-PPAR α signaling pathway. *J Biol Chem*. 2020;295(50):17310–22.
20. White ES, Thannickal VJ, Carskadon SL, Dickie EG, Livant DL, Markwart S, et al. Integrin α 4 β 1 regulates migration across basement membranes by lung fibroblasts: a role for phosphatase and tensin homologue deleted on chromosome 10. *Am J Respir Crit Care Med*. 2003;168(4):436–42.
21. Kim HS, Yoo HJ, Lee KM, Song HE, Kim SJ, Lee JO, et al. Stearic acid attenuates profibrotic signalling in idiopathic pulmonary fibrosis. *Respirology*. 2021;26(3):255–63.
22. Sathyanarayan A, Mashek MT, Mashek DG. ATGL Promotes autophagy/lipophagy via SIRT1 to control hepatic lipid droplet catabolism. *Cell Rep*. 2017;19(1):1–9.
23. Peyser R, MacDonnell S, Gao Y, Cheng L, Kim Y, Kaplan T, et al. Defining the activated fibroblast population in lung fibrosis using single-cell sequencing. *Am J Respir Cell Mol Biol*. 2019;61(1):74–85.
24. Travaglini KJ, Nabhan AN, Penland L, Sinha R, Gillich A, Sit RV, et al. A molecular cell atlas of the human lung from single-cell RNA sequencing. *Nature*. 2020;587(7835):619–25.

25. Phan T, Paliogiannis P, Nasrallah GK, Giordo R, Eid AH, Fois AG, et al. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. *Cell Mol Life Sci.* 2021;78(5):2031–57.
26. Zhang M, Zhang Y, Roth M, Zhang L, Shi R, Yang X, et al. Sirtuin 3 inhibits airway epithelial mitochondrial oxidative stress in cigarette smoke-induced COPD. *Oxid Med Cell Longev.* 2020;2020:7582980.
27. Dikalov S, Itani H, Richmond B, Vergeade A, Rahman S, Boutaud O, et al. Tobacco smoking induces cardiovascular mitochondrial oxidative stress, promotes endothelial dysfunction, and enhances hypertension. *Am J Physiol Heart Circ Physiol.* 2019;316(3):H639–46.
28. Du S, Li C, Lu Y, Lei X, Zhang Y, Li S, et al. Dioscin alleviates crystalline silica-induced pulmonary inflammation and fibrosis through promoting alveolar macrophage autophagy. *Theranostics.* 2019;9(7):1878–92.
29. Gouzou M, Ramezanpour M, Bassiouni A, Psaltis AJ, Wormald PJ, Vreugde S. Antibiotics affect ROS production and fibroblast migration in an in-vitro model of Sinusoidal wound healing. *Front Cell Infect Microbiol.* 2020;10:110.
30. Goh KY, He L, Song J, Jinno M, Rogers AJ, Sethu P, et al. Mitoquinone ameliorates pressure overload-induced cardiac fibrosis and left ventricular dysfunction in mice. *Redox Biol.* 2019;21: 101100.
31. Turkseven S, Bolognesi M, Brocca A, Pesce P, Angeli P, Di Pascoli M. Mitochondria-targeted antioxidant mitoquinone attenuates liver inflammation and fibrosis in cirrhotic rats. *Am J Physiol Gastrointest Liver Physiol.* 2020;318(2):G298–304.
32. Miao J, Liu J, Niu J, Zhang Y, Shen W, Luo C, et al. Wnt/beta-catenin/RAS signaling mediates age-related renal fibrosis and is associated with mitochondrial dysfunction. *Aging Cell.* 2019;18(5): e13004.
33. Rossman MJ, Santos-Parker JR, Steward C, Bispham NZ, Cuevas LM, Rosenberg HL, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. *Hypertension.* 2018;71(6):1056–63.
34. Suryadevara V, Ramchandran R, Kamp DW, Natarajan V. Lipid mediators regulate pulmonary fibrosis: potential mechanisms and signaling pathways. *Int J Mol Sci.* 2020;21(12):4257.
35. Jung MY, Kang JH, Hernandez DM, Yin X, Andrianifahanana M, Wang Y, et al. Fatty acid synthase is required for profibrotic TGF-beta signaling. *FASEB J.* 2018;32(7):3803–15.
36. Nambiar S, Tan D, Clynick B, Bong SH, Rawlinson C, Gummer J, et al. Untargeted metabolomics of human plasma reveal lipid markers unique to chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. *Proteomics Clin Appl.* 2021;15:e2000039.
37. Jadhav S, Ajay AK, Trivedi P, Seematti J, Pellegrini K, Craciun F, et al. RNA-binding protein Musashi homologue 1 regulates kidney fibrosis by translational inhibition of p21 and numb mRNA. *J Biol Chem.* 2016;291(27):14085–94.
38. Meng Y, Pan M, Zheng B, Chen Y, Li W, Yang Q, et al. Autophagy attenuates angiotensin II-induced pulmonary fibrosis by inhibiting redox imbalance-mediated NOD-like receptor family pyrin domain containing 3 inflammasome activation. *Antioxid Redox Signal.* 2019;30(4):520–41.
39. Suroli R, Li FJ, Wang Z, Li H, Dsouza K, Thomas V, et al. Vimentin intermediate filament assembly regulates fibroblast invasion in fibrogenic lung injury. *JCI Insight.* 2019;4(7):e123253.
40. Morishita H, Mizushima N. Diverse cellular roles of autophagy. *Annu Rev Cell Dev Biol.* 2019;35:453–75.
41. Grefhorst A, van de Peppel IP, Larsen LE, Jonker JW, Holleboom AG. The role of lipophagy in the development and treatment of non-alcoholic fatty liver disease. *Front Endocrinol.* 2020;11: 601627.
42. Zhang T, Chi Y, Kang Y, Lu H, Niu H, Liu W, et al. Resveratrol ameliorates podocyte damage in diabetic mice via SIRT1/PGC-1alpha mediated attenuation of mitochondrial oxidative stress. *J Cell Physiol.* 2019;234(4):5033–43.
43. Tan M, Tang C, Zhang Y, Cheng Y, Cai L, Chen X, et al. SIRT1/PGC-1alpha signaling protects hepatocytes against mitochondrial oxidative stress induced by bile acids. *Free Radic Res.* 2015;49(8):935–45.
44. Liu T, Ma X, Ouyang T, Chen H, Xiao Y, Huang Y, et al. Efficacy of 5-aminolevulinic acid-based photodynamic therapy against keloid compromised by downregulation of SIRT1-SIRT3-SOD2-mROS dependent autophagy pathway. *Redox Biol.* 2019;20:195–203.
45. Zeng Z, Cheng S, Chen H, Li Q, Hu Y, Wang Q, et al. Activation and overexpression of Sirt1 attenuates lung fibrosis via P300. *Biochem Biophys Res Commun.* 2017;486(4):1021–6.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

